KANAZAWA, Japan, Feb. 10, 2020 /PRNewswire/ -- Researchers at Kanazawa University report in the Journal of Thoracic Oncology a promising novel approach for a combined treatment of the most common type of lung cancer and associated secondary cancers in the central nervous system. The approach lies in combining two cancer drugs, with one compensating for a resistance side effect of the other.
In 20 40% of patients with cancer, metastasis (the development of secondary tumors) in the central nervous system (CNS) occurs. CNS metastatis impacts negatively on a patient's quality of life, and is associated with a poor health prognosis. In a form of cancer known as ALK-rearranged non-small-cell lung cancer (NSCLC), CNS metastatis is known to persist when drugs targeting primary tumors are used.Now, Seiji Yano from Kanazawa University and colleagues have investigated the origins for the resistence to such drugs, and tested a new therapeutic strategy on a mouse model.
The researchers looked at the drug alectinib.Although used in standard treatments for advanced ALK-rearranged NSCLC, approximately 20 30% of patients treated with alectinib develop CNS metastatis, which is attributed to acquired resistance to the drug.
By treating mice first injected with tumor cells with alectinib daily for 16 weeks, the scientists obtained a mouse model displaying alectinib resistance.By biochemical analyses of the mouse brains, Yano and colleagues were able to link the resistance to the activation of a protein known as epidermal growth factor receptor (EGFR).This activation is, in turn, a result of an increase in production of amphiregulin (AREG), a protein that binds to EGFR and in doing so 'activates' it.
Based on this insight, the researchers tested the effect of administering drugs used for inhibiting the action of EGFR in combination with alectinib treatment.The experiments showed that a combination treatment of alctinib with either erlotinib or osimertinib two existing EGFR-inibiting drugs prevented the progression of CNS metastasis, controlling the condition for over 30 days.
The scientists conclude that the combined use of alectinib and EGFR-inhibitors could overcome alectinib resistance in the mouse model of leptomeningeal carcinomatosis (LMC), a particular type of CNS metastasis.Quoting Yano and colleagues: "Our findings may provide rationale for clinical trials to investigate the effects of novel therapies dual-targeting ALK and EGFR in ALK-rearranged NSCLC with alectinib-resistant LMC."
Background
Non-small-cell lung cancer
Non-small-cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) are the two types of lung cancer. 85% of all lung cancers are of the NSCLC type. NSCLCs are less sensitive to chemotherapy than SCLCs, making drug treatment of the highest importance.
Alectinib is a drug used for treating NSCLC, with good efficiency. However, 20-30% of patients taking the drug develop secondary cancer in the central nervous system (CNS), which is associated with an acquired resistance to alectinib.Seiji Yano from Kanazawa University and colleagues have now made progress towards a novel therapy against this resistance: a combination of alectinib with other drugs.
Epidermal growth factor receptor inhibitors
The drugs that Yano and colleagues tested in combination with alectinib on a mouse model were of a type known as epidermal growth factor receptor (EGFR) inhibitors, including osimertinib and erlotinib. Both are being used as medication for treating NSCLC.The former was approved in 2017 as cancer treatment by the U.S. Food and Drug Administration and the European Commission.Yano and colleagues obtained results showing that EGFR inhibitors counteract resistance to alectinib and have therefore potential in novel therapies for NSCLC and secondary cancers in the CNS.
Reference
Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-mei Zheng, Yi-Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, and Seiji Yano. Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer, Journal of Thoracic Oncology, published online on January 21, 2020.
Story continues
DOI: 10.1016/j.jtho.2020.01.001
URL: https://www.sciencedirect.com/science/article/pii/S1556086420300228
About Nano Life Science Institute (WPI-NanoLSI)
Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.
About Kanazawa University
http://www.kanazawa-u.ac.jp/e/
As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.
The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.
Further information
Hiroe Yoneda Vice Director of Public Affairs WPI Nano Life Science Institute (WPI-NanoLSI) Kanazawa University Kakuma-machi, Kanazawa 920-1192, Japan Email: nanolsi-office@adm.kanazawa-u.ac.jpTel: +81-(76)-234-4550
View original content:http://www.prnewswire.com/news-releases/kanazawa-university-research-combined-drug-treatment-for-lung-cancer-and-secondary-tumors-301001822.html
SOURCE Kanazawa University
Read the original here:
Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance
- Nano Medicine: Meaning, Advantages and Disadvantages - BioTechnology Notes - December 18th, 2022
- www.the-scientist.com - December 18th, 2022
- Applications of Nanotechnology - National Nanotechnology Initiative - December 18th, 2022
- Nanotechnology Timeline | National Nanotechnology Initiative - October 29th, 2022
- Nano based drug delivery systems: recent developments and future ... - October 21st, 2022
- The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review - Cureus - September 16th, 2022
- 'Glass bubble' nanocarrier boosts effects of combination therapy for pancreatic cancer - UCLA Newsroom - September 16th, 2022
- International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. - ETHealthWorld - September 16th, 2022
- Reebok Nano X2 Adventure Review: A Wild Way to Log Your Workouts - Gear Patrol - August 30th, 2022
- PhD within Particle Engineering job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 306487 - Times Higher Education - August 30th, 2022
- Nanoparticles' Role in Eliminating Cancer Cells - MedTech Outlook - August 22nd, 2022
- The first female astronaut from a North African nation will be a Tunisian military aviator - Atalayar - August 22nd, 2022
- Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition | npj Digital Medicine - Nature.com - August 22nd, 2022
- Reebok's Nano X2 Adventure Helps You Take Your Workouts Anywhere - Gear Patrol - August 14th, 2022
- How Houston's nonprofit funds early research that leads to breakthroughs like the COVID vaccine - Houston Chronicle - August 14th, 2022
- Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and... - July 27th, 2022
- Nanorobots Market to close to USD 19576.43 million with CAGR of 12.23% during the forecast period to 2029 - Digital Journal - July 27th, 2022
- Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development... - July 27th, 2022
- Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study - Business Wire - July 19th, 2022
- Columbia Business School and Columbia Engineering to Offer New "Dual MBA/Executive MS in Engineering and Applied Science" Program - Yahoo... - July 19th, 2022
- Internet of Nano Things Market is Poised to Grow at a CAGR of 24.12% during the Forecast Period of 2022-2031 - Digital Journal - July 11th, 2022
- Notable Thermal and Mechanical Properties of New Hybrid Nanostructures - AZoM - July 11th, 2022
- Eggshell and bioceramics: Break an egg to fix a tooth or two - BusinessLine - July 11th, 2022
- Nanomedicine in Central Nervous System Injury and Repair Market Share, Regional Growth Analysis, Upcoming Trends, Growth Factors and Leading... - July 11th, 2022
- Nanorobotics Market 2022 Research Report Analysis from Perspective of Segmentation and Industry Growth 2030 Designer Women - Designer Women - July 11th, 2022
- Artificial Intelligence in Medical Diagnostics Market Worth $9.38 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - July 11th, 2022
- $2.38M to test nano-engineered brain cancer treatment in mice - University of Michigan News - June 22nd, 2022
- New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The... - June 22nd, 2022
- Global Advanced Functional Materials Market To Be Driven By The Surging Demand From Medical Sector In The Forecast Period Of 2021-2026 Designer Women... - June 22nd, 2022
- An effective nano drug delivery and combination therapy for the treatment of Tuberculosis | Scientific Reports - Nature.com - June 13th, 2022
- Nanotechnology is poised to shape the future of Healthcare - ETHealthWorld - June 4th, 2022
- New Silence ALS Initiative is Giving Hope to Nano-Rare Patients - BioSpace - June 4th, 2022
- Nanotechnology in the Global Medical Applications Market 2022, Featuring Profiles of Abbott, Abraxis Bioscience, Elan, Orthovita, EyePoint... - May 15th, 2022
- Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian - May 2nd, 2022
- Nanomedicine Market to 2030 Insights and Forecast with Impact of COVID-19 | Abbott Laboratories, DiaSorin S.p.A, Invitae Corporation, Mallinckrodt... - May 2nd, 2022
- Cancer and Nanotechnology - National Cancer Institute - April 19th, 2022
- Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 - Digital Journal - April 19th, 2022
- ERDC researchers analyze resilience in nanotechnology supply chains - erdc.usace.army.mil - April 19th, 2022
- Nano Products Online Store | Nanoproducts, Nanoparticles ... - April 6th, 2022
- The Conrad Prebys Foundation to Support the Discovery and Development of Personalized ASO Medicines for Nano-rare Patients - Business Wire - March 25th, 2022
- Space the next frontier for cancer treatment? - Australian Jewish News - March 25th, 2022
- ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of... - January 20th, 2022
- Surface Modification and Size Contribute to Nanoplastic Toxicity - AZoNano - January 20th, 2022
- Frontiers | Nanomedicine: Principles, Properties, and ... - January 5th, 2022
- Nanotechnology In Medicine: Huge Potential, But What Are ... - January 5th, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 5th, 2022
- 2009 show based on conspiracy theories is shared as proof of WHO working on COVID-19 vaccines to create permanent sterility - Factly - January 5th, 2022
- How to Improve Infectious Diseases with Nanotechnology - CIO Applications - January 5th, 2022
- Biodistribution of sphingolipid nanoemulsions with 68Ga | IJN - Dove Medical Press - August 31st, 2021
- Matrix Meats Adds to Team as Interest in Cultivated Meat Grows - PRNewswire - July 21st, 2021
- Nanomedicine in Central Nervous System Injury and Repair Market Report- Trends Key Programs Analysis and Competitive Landscape Analysis The Manomet... - June 23rd, 2021
- Nanomedicine is transforming healthcare innovation - Korea IT Times - June 6th, 2021
- The Future of Cancer Treatment Using Nanotechnology - AZoNano - June 6th, 2021
- Thomas Jefferson Awards Highlight Research and Service to the University - UVA Today - June 6th, 2021
- Global Nanobots Market 2020 | Research Report Covers | (COVID-19 Analysis) | Industry Research, Drivers, Top Trends | Global Analysis And Forecast to... - October 31st, 2020
- Nanox Signs With Ambra Health to Enable Image Access and Transfer with US Hospitals and Medical imaging Providers - BioSpace - October 31st, 2020
- Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 29th, 2020
- What is Nanoscience? | Outlook and How to Invest | INN - Investing News Network - September 23rd, 2020
- Interview: The NDB team on its revolutionary nano-diamond batteries - New Atlas - August 29th, 2020
- Opportunities in the World Nanotechnology Market to 2025 - Application of Nanotechnology in Wastewater Treatment and Enhanced Renewable Energy Driving... - August 12th, 2020
- Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters - BioSpace - June 17th, 2020
- Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire - June 17th, 2020
- Coronavirus threat to global Healthcare Nanotechnology (Nanomedicine) Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type... - June 15th, 2020
- Kanazawa University Research: Cell Removal as the Result of a Mechanical Instability - PR Newswire UK - June 15th, 2020
- Impact of Covid-19 on Nano Chemotherapy Market is Expected to Grow at an active CAGR by Forecast to 2026 | Top Players Dell Wyse, IBM, Microsoft -... - June 15th, 2020
- Evergreen Medical Acupuncture is now offering its own supplement and herbal products, Dr. Ficks Functional Farmacy! - TippNews DAILY - June 10th, 2020
- Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca - May 24th, 2020
- Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press - May 10th, 2020
- The future of medicine - Switzer Financial News - May 10th, 2020
- All your questions about how to wear a face mask -- answered - Action News Now - April 26th, 2020
- Edited Transcript of NANO earnings conference call or presentation 6-Feb-20 9:30pm GMT - Yahoo Finance - February 11th, 2020
- Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - BioSpace - February 11th, 2020
- Nano Medicine: Meaning, Advantages and Disadvantages - February 6th, 2020
- The Future Of Nano Medicine - February 6th, 2020
- VVUS Stock Jumps 70% on FDA Nod for New Formulation of Pancreaze - MicroSmallCap - February 6th, 2020
- Is the Lieber Arrest Linked to Military Brain Research and China? - Bryen's Blog - February 6th, 2020
- A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press - January 10th, 2020
- Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News - January 10th, 2020
- Triple Negative Breast Cancer Treatment Market Combining Therapies - Communal News - January 10th, 2020
- Our top 20 features of 2019 - COVER - January 5th, 2020